These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 17670914)
1. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mistry SJ; Bank A; Atweh GF Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914 [TBL] [Abstract][Full Text] [Related]
2. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Miceli C; Tejada A; Castaneda A; Mistry SJ Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mistry SJ; Atweh GF Mol Cancer Ther; 2006 Dec; 5(12):3248-57. PubMed ID: 17172428 [TBL] [Abstract][Full Text] [Related]
4. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Iancu C; Mistry SJ; Arkin S; Atweh GF Cancer Res; 2000 Jul; 60(13):3537-41. PubMed ID: 10910066 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Pasquier E; Honore S; Pourroy B; Jordan MA; Lehmann M; Briand C; Braguer D Cancer Res; 2005 Mar; 65(6):2433-40. PubMed ID: 15781659 [TBL] [Abstract][Full Text] [Related]
6. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534 [TBL] [Abstract][Full Text] [Related]
7. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism. Derry WB; Wilson L; Jordan MA Cancer Res; 1998 Mar; 58(6):1177-84. PubMed ID: 9515803 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700 [TBL] [Abstract][Full Text] [Related]
9. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice. Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016 [TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. Dicker AP; Williams TL; Iliakis G; Grant DS Am J Clin Oncol; 2003 Jun; 26(3):e45-53. PubMed ID: 12796615 [TBL] [Abstract][Full Text] [Related]
11. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines. Lin X; Liao Y; Xie J; Liu S; Su L; Zou H Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611 [TBL] [Abstract][Full Text] [Related]
12. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mistry SJ; Atweh GF Mt Sinai J Med; 2002 Oct; 69(5):299-304. PubMed ID: 12415323 [TBL] [Abstract][Full Text] [Related]
13. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Tran TC; Sneed B; Haider J; Blavo D; White A; Aiyejorun T; Baranowski TC; Rubinstein AL; Doan TN; Dingledine R; Sandberg EM Cancer Res; 2007 Dec; 67(23):11386-92. PubMed ID: 18056466 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antiangiogenic potential of AQ4N. O'Rourke M; Ward C; Worthington J; McKenna J; Valentine A; Robson T; Hirst DG; McKeown SR Clin Cancer Res; 2008 Mar; 14(5):1502-9. PubMed ID: 18316575 [TBL] [Abstract][Full Text] [Related]
17. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Sun HL; Tsai AC; Pan SL; Ding Q; Yamaguchi H; Lin CN; Hung MC; Teng CM Clin Cancer Res; 2009 Aug; 15(15):4904-14. PubMed ID: 19622586 [TBL] [Abstract][Full Text] [Related]
18. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis. Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel taxol-sensitive kinase activity associated with the cytoskeleton. Wang Y; Duncan R; Ann DK; Hamm-Alvarez SF Biochem Biophys Res Commun; 2000 Nov; 277(3):525-30. PubMed ID: 11061987 [TBL] [Abstract][Full Text] [Related]
20. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. Ng DC; Lin BH; Lim CP; Huang G; Zhang T; Poli V; Cao X J Cell Biol; 2006 Jan; 172(2):245-57. PubMed ID: 16401721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]